Table 3. Outcomes after lithium administration.
| Patient | lithium start day after endoscopy | lithium administration duration, days | Intestinal GVHD Response | Survival (S) at 2 years or day expired* | Causes of death |
|---|---|---|---|---|---|
| 1 | 0 | 56 | CR | S | |
| 2 | 0 | 43 | CR | S | |
| 3 | 1 | 57 | CR | S | Relapse (1730†) 1767* |
| 4 | 2 | 44 | CR | S | Relapse (611†, 2151†) 2181* |
| 5 | 3 | 108 | CR | S | |
| 6 | 3 | 40 | CR | S | |
| 7 | 3 | 30 | CR | S | |
| 8 | 1 | 19 | CR | 714 | cGVHD, BOS |
| 9 | 7 | 172‡ | CR | 302 | BOS, cGVHD |
| 10 | 0 | 25 | NR | 39 | GVHD, CMV, Infection |
| 11 | 5 | 31 | NR | 33 | MOF, GVHD, Infection |
| 12 | 6 | 19 | PR | 58 | Liver GVHD, Infection |
| 13 | 0 | 7 | NR | 65 | DAH, GVHD, Infection |
| 14 | 9 | 34 | NR | 63 | GVHD, Infection |
| 15 | 22 | 56 | NR | 85 | GVHD |
| 16 | 2 | 8 | NR | 27 | HUS, GVHD, MOF |
| 17 | 3 | 8 | NR | 41 | GVHD |
| 18 | 10 | 8 | NR | 11 | GVHD |
| 19 | 11 | 13 | NR | 24 | GVHD, CMV |
| 20 | 10 | 18 | CR | 210 | Infection, GVHD |
NR indicates no response; ARDS, adult respiratory distress syndrome; BOS, bronchiolitis obliterans syndrome; DAH, diffuse alveolar hemorrhage; HUS, hemolytic uremic syndrome; cGVHD, chronic GVHD; CMV, cytomegalovirus; and MOF, multiorgan failure.
*day expired.
†day of recurrent malignancy after start of lithium.
‡lithium withheld day 8–19